Nichi-Iko Has An Ally In Argentina On Infliximab

Strikes Deal With Laboratorio Elea To Market Remicade Biosimilar

 
• By Dave Wallace

Laboratorio Elea has struck a deal with Nichi-Iko Pharmaceutical to market the Japanese firm’s infliximab biosimilar in Argentina.

Argentina South America Map
Elea will market Nichi-Iko’s infliximab in Argentina • Source: Alamy

More from Deals

More from Business